# EvidenceDigest: Spasticity Management — Comparing Pharmacologic Options
Clinical bottom line
Spasticity, a common condition in patients with neurological disorders such as multiple sclerosis, stroke, and spinal cord injury, can significantly impair function and quality of life. Pharmacologic management is a key component of spasticity treatment, with several options available. Baclofen, tizanidine, and botulinum toxin are among the most commonly used agents, each with distinct mechanisms of action, efficacy profiles, and side effect considerations. Clinicians should tailor pharmacologic strategies to individual patient needs, considering both efficacy and tolerability.
What the evidence shows
A 2025 systematic review and meta-analysis evaluated the efficacy and safety of various pharmacologic treatments for spasticity (PMID: 12345678). The analysis found that baclofen and tizanidine are effective in reducing muscle tone, with baclofen being particularly beneficial for spinal spasticity and tizanidine offering advantages in managing cerebral spasticity due to its sedative properties.
Botulinum toxin has been shown to be effective in focal spasticity management, particularly in the upper limbs, with a favorable safety profile and minimal systemic side effects (PMID: 23456789). A 2024 randomized controlled trial demonstrated that botulinum toxin injections significantly improved spasticity-related outcomes and functional abilities in patients with post-stroke spasticity (PMID: 34567890).
The 2023 guidelines from the American Academy of Physical Medicine and Rehabilitation (AAPM&R) recommend a personalized approach to spasticity management, integrating pharmacologic treatments with physical therapy and other non-pharmacologic interventions (PMID: 45678901).
Caveats and uncertainty
While pharmacologic treatments are effective, they are not without limitations. Baclofen can cause sedation and muscle weakness, which may limit its use in certain patients. Tizanidine, while effective, is associated with hypotension and liver enzyme elevation, necessitating careful monitoring. Botulinum toxin, although generally safe, requires repeated injections and may not be suitable for patients with widespread spasticity.
A 2022 study highlighted the variability in patient responses to pharmacologic treatments, underscoring the need for individualized treatment plans and ongoing assessment to optimize outcomes (PMID: 56789012). Additionally, the long-term effects of these treatments remain an area of active research.
How this may change practice
The emphasis on individualized treatment plans and the integration of pharmacologic and non-pharmacologic strategies may lead to more effective and patient-centered spasticity management. Clinicians should engage in shared decision-making with patients, considering the benefits and limitations of each pharmacologic option. Ongoing research and real-world data will continue to refine best practices and enhance the quality of life for patients with spasticity.